Polar Capital Holdings Plc Acquires 8.47% Stake in Enliven Therapeutics, Inc. (ELVN)

Polar Capital Holdings Plc, along with its affiliates Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund, filed a Schedule 13G/A on May 15, 2026, disclosing a significant stake in Enliven Therapeutics, Inc. (ELVN). The reporting entities collectively hold 59,800,406 shares of common stock, representing 8.47% of the company's outstanding shares based on the issuer's most recent Form 10-Q. This filing marks a substantial increase from a previous 0% ownership level reported in the provided metadata, reflecting a new major position by the London-based investment manager. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. Polar Capital Holdings Plc maintains sole voting and dispositive power over the reported shares. The event triggering this amendment occurred on March 31, 2026, and the filing was executed by Nicholas Farren, Chief Operating Officer of the reporting entities.